JERUSALEM, October 6, 2017 /PRNewswire/ --
Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that
management will participate in the Oppenheimer Specialty Pharma
Summit to be held October 11, 2017 at
the Sofitel Hotel in New York
City.
Date: Wednesday, October 11, 2017
Venue: Sofitel New York Hotel
Format: One-on-One Meetings with Investors
Presenter: Jeffrey A.
Meckler, Chief Executive Officer of Intec Pharma
The investor presentation will be posted to the Events section
of the Company's website at http://www.intecpharma.com.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is being developed for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients, and
AP-CBD/THC, an Accordion Pill with the two primary cannabinoids
contained in Cannabis sativa, cannabidiol (CBD) and
tetrahydrocannabinol (THC), which is being developed for various
indications including low back neuropathic pain and
fibromyalgia.
Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com
SOURCE Intec Pharma Ltd.